Ipca’s formulation business has emerged as most competitive in the evolving generic space with core focus on vertical integration.

We have a diverse product portfolio catering to major therapeutic segments in virtually every dosage form – Oral solids, Powder for suspension and Small volume injections (dry & liquid).

Having established the essence and resolve to compete in the growing generic arena we have fortified our capabilities in terms of infrastructure with 4 dedicated manufacturing facilities catering to regulated markets, having accreditation from Health Canada, Government of Oberfranken-Germany, Halmed-Croatia, MHRA-UK, TGA-Australia, SAHPRA-South Africa, and WHO-Geneva. Our state of the art facilities are designed with an eye on addressing the economies of scale offering a competitive edge.

Sound scientific developments, team of experienced scientist and regulatory expertise has aided development of a steadily growing portfolio of over 100 product dossiers.

Our Business Development team collaborates with potential business partners across continents establishing presence of our products in multiple geographies such as North America, Europe, UK, Australia, New Zealand and South Africa, through various business models – Dossier out-licensing, Contract manufacturing & supply and CRAMs.

We have now embarked on a new journey in the developed nations, taking nascent steps in front end marketing with the acquisition of Bayshore Pharmaceuticals in USA and launch of our UK operations under Ipca label.